Department of Traditional Chinese Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Department of Oncology 1, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Biotechnol Genet Eng Rev. 2024 Dec;40(4):3019-3034. doi: 10.1080/02648725.2023.2203004. Epub 2023 Apr 21.
Colorectal cancer is a type of cancer that affects the colon or rectum, which are part of the digestive system. It usually develops from small growths called polyps that can turn cancerous over time. This study aimed to investigate the effects of Jianpi Yiqi prescription on clinical symptoms, inflammation, oxidative stress, efficacy, and adverse reactions in colorectal cancer (CRC) patients. A total of 84 CRC patients treated at a hospital from January 2020 to December 2021 were randomly divided into two groups: the conventional chemotherapy group and the Jianpi Yiqi prescription group. Patients in the Jianpi Yiqi group received traditional Chinese medicine on top of conventional chemotherapy. Clinical symptoms and plasma biomarkers were analyzed and compared between the two groups. Results showed that there were significant differences between the two groups before therapy. After therapy, the Jianpi Yiqi group had lower TCM symptom scores, inflammatory factor indices, MDA and SOD levels, and incidence of adverse reactions than the conventional group. Moreover, the total effective rate and tumor stability rate of the Jianpi Yiqi group were higher than those of the conventional group. The study concluded that Jianpi Yiqi prescription had better clinical efficacy in treating CRC patients compared to conventional chemotherapy, with fewer adverse reactions and better inhibition of inflammatory factors and oxidative stress. Overall, this study suggests that Jianpi Yiqi prescription could be a promising complementary therapy for CRC patients, but more research is needed to confirm these findings.
结直肠癌是一种影响结肠或直肠的癌症，它们是消化系统的一部分。它通常由随着时间的推移可能癌变的小生长物（称为息肉）发展而来。本研究旨在探讨健脾益气方对结直肠癌（CRC）患者临床症状、炎症、氧化应激、疗效和不良反应的影响。2020 年 1 月至 2021 年 12 月，一家医院收治的 84 例 CRC 患者被随机分为两组：常规化疗组和健脾益气方组。健脾益气组患者在常规化疗的基础上接受中药治疗。分析比较两组患者的临床症状和血浆生物标志物。结果显示，两组患者治疗前存在显著差异。治疗后，健脾益气组 TCM 症状评分、炎症因子指标、MDA 和 SOD 水平及不良反应发生率均低于常规组。此外，健脾益气组的总有效率和肿瘤稳定率均高于常规组。研究得出结论，与常规化疗相比，健脾益气方治疗 CRC 患者的临床疗效更好，不良反应更少，对炎症因子和氧化应激的抑制作用更好。总的来说，这项研究表明，健脾益气方可能是 CRC 患者有前途的辅助治疗方法，但需要更多的研究来证实这些发现。
